Fate Therap(FATE.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Fate Therap
FATE.US
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co.
1.911 T
FATE.USMarket value -Rank by Market Cap -/-

Financial Score

17/03/2026 Update
D
BiotechnologyIndustry
Industry Ranking271/398
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-51.84%E
    • Profit Margin-2051.08%E
    • Gross Margin-1282.77%E
  • Growth ScoreE
    • Revenue YoY-51.24%E
    • Net Profit YoY26.82%B
    • Total Assets YoY-27.63%E
    • Net Assets YoY-35.00%E
  • Cash ScoreD
    • Cash Flow Margin-4.88%D
    • OCF YoY-51.24%E
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreB
    • Gearing Ratio35.04%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference

    Market Beat·
    US
    BIB
    +1.99%
    US
    BBH
    +0.49%
    US
    IBB
    +0.98%
    Market Beat·
    US
    BIB
    +1.99%
    US
    BBH
    +0.49%
    US
    IBB
    +0.98%

    Fate Therapeutics Q4 Earnings Summary & Key Takeaways

    benzinga_article·
    US
    FATE
    -0.85%
    US
    XBI
    +1.71%
    US
    SBIO
    +1.73%
    benzinga_article·
    US
    FATE
    -0.85%
    US
    XBI
    +1.71%
    US
    SBIO
    +1.73%

    Fate Therap | 10-K: FY2025 Revenue Beats Estimate at USD 6.646 M

    LB filings·
    US
    FATE
    -0.85%
    LB filings·
    US
    FATE
    -0.85%

    Fate Therapeutics reports lower Q4 collaboration revenue

    Reuters·
    US
    IBBQ
    +0.92%
    US
    BBH
    +0.49%
    US
    FATE
    -0.85%
    Reuters·
    US
    IBBQ
    +0.92%
    US
    BBH
    +0.49%
    US
    FATE
    -0.85%

    Fate Therapeutics gewährt neuem Mitarbeiter Aktienoptionen und RSUs als Einstiegsvergütung

    Reuters·
    US
    IBBQ
    +0.92%
    US
    IBB
    +0.98%
    US
    PBE
    +1.39%
    Reuters·
    US
    IBBQ
    +0.92%
    US
    IBB
    +0.98%
    US
    PBE
    +1.39%
    © 2026 Longbridge｜Disclaimer